Skip to main content
. 2017 Dec 1;117(2):238–245. doi: 10.1160/TH16-03-0224

Figure 1: Study design.

Figure 1: Study design

. All cohorts: n=10 (8 active + 2 placebo); 7 days between patient dosing within a cohort and 3 days between cohorts; in Period 2, ciraparantag or placebo administered approximately 3 h post edoxaban (EDX). The 25 mg dosing cohort was repeated using the WBCT to achieve a total of eight dosing cohorts.